Office of Student Affairs, Baylor University, Waco, TX, USA.
Office of Student Affairs, Baylor College of Medicine, Houston, TX, USA.
Ann Transplant. 2024 Jan 9;29:e941931. doi: 10.12659/AOT.941931.
BACKGROUND Patients with high-acuity liver failure have increased access to marginal and split liver options, owing to historically high waitlist mortality rates. While most research states that donor liver quality has no impact on patients with high-acuity illness, there have been inconsistencies in recent research on how liver quality impacts post-transplant outcomes for these patients. We aimed to quantify donor liver quality with various post-transplantation patient outcomes for patients with high-acuity illness. MATERIAL AND METHODS Using the liver donor risk index (LDRI), model for end stage liver disease (MELD), and clinically relevant recipient factors, we used multivariate logistic regression to analyze how donor liver quality affects varying measures of patient outcomes for 9923 high-acuity patients from June 18, 2013, to June 18, 2022. RESULTS Using LDRI, high-quality livers had a significant protective impact on high-acuity patient mortality, compared with low-quality livers (OR=0.695 [0.549, 0.879], P=0.002). High-quality livers also had significant impact on graft survival (OR=0.706 [0.558, 0.894], P=0.004). Two sensitivity patient mortality analyses, excluding patients with status 1A and hepatocellular carcinoma, showed significant protective findings for high-quality livers. High-quality livers had insignificant outcomes on long-term survivor mortality, length of hospitalization, and primary non-function outcomes, compared with low-quality donor livers. CONCLUSIONS While our findings suggest donor quality has an impact on high-acuity patient outcomes, these findings indicate further research is needed in intent-to-treat analysis on clinical offer data to provide a clearer finding of how donor quality affects patients with high-acuity illness.
由于历史上高等待名单死亡率,患有急性肝衰竭的患者获得边缘和劈裂肝的机会增加。虽然大多数研究表明供体肝脏质量对患有急性疾病的患者没有影响,但最近的一些研究在供体肝脏质量如何影响这些患者的移植后结果方面存在不一致。我们旨在量化具有不同术后患者结局的供体肝脏质量,以评估患有急性疾病的患者。
使用肝供体风险指数(LDRI)、终末期肝病模型(MELD)和临床相关受者因素,我们使用多变量逻辑回归分析了供体肝脏质量如何影响 9923 例 2013 年 6 月 18 日至 2022 年 6 月 18 日患有急性疾病的患者的各种患者结局衡量标准。
使用 LDRI,高质量肝脏与低质量肝脏相比,对急性患者死亡率有显著的保护作用(OR=0.695 [0.549, 0.879], P=0.002)。高质量肝脏对移植物存活率也有显著影响(OR=0.706 [0.558, 0.894], P=0.004)。两项排除 1A 期和肝细胞癌患者的敏感性患者死亡率分析显示,高质量肝脏对患者有显著的保护作用。与低质量供体肝脏相比,高质量肝脏在长期幸存者死亡率、住院时间和原发性无功能结局方面无显著差异。
虽然我们的研究结果表明供体质量对急性患者结局有影响,但这些结果表明,在基于意向治疗分析的临床供体数据中,需要进一步研究,以更清楚地发现供体质量如何影响患有急性疾病的患者。